Biofrontera (BFRI) to Release Earnings on Friday

Biofrontera (NASDAQ:BFRI) is expected to be posting its Q4 2025 results after the market closes on Friday, April 3rd. Analysts expect Biofrontera to post earnings of $0.1950 per share and revenue of $16.1460 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 19, 2026 at 10:00 AM ET.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings data on Thursday, March 19th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.21. The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $16.15 million. Biofrontera had a negative net margin of 25.26% and a negative return on equity of 1,236.11%. On average, analysts expect Biofrontera to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biofrontera Stock Up 13.8%

Shares of NASDAQ:BFRI opened at $0.92 on Thursday. The company has a market cap of $10.73 million, a price-to-earnings ratio of -0.89 and a beta of 0.63. The firm’s 50-day simple moving average is $0.87 and its 200-day simple moving average is $0.88. The company has a quick ratio of 1.40, a current ratio of 1.52 and a debt-to-equity ratio of 0.44. Biofrontera has a fifty-two week low of $0.54 and a fifty-two week high of $1.19.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Geode Capital Management LLC boosted its position in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the quarter. Geode Capital Management LLC owned approximately 0.56% of Biofrontera worth $37,000 at the end of the most recent reporting period. 10.08% of the stock is owned by institutional investors and hedge funds.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.